Revance Therapeutics, Inc.
$ 3.65
0.00%
04 Mar - close price
- Market Cap 381,024,000 USD
- Current Price $ 3.65
- High / Low $ 3.65 / 3.65
- Stock P/E N/A
- Book Value -1.55
- EPS -3.34
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -20.97 %
- 52 Week High 0.00
- 52 Week Low 0.00
About
Revance Therapeutics, Inc., a biotechnology company, is dedicated to the development, manufacture, and marketing of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company is headquartered in Newark, California.
Analyst Target Price
$9.47
Quarterly Earnings
| Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2024-11-04 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-08 | 2023-08-08 | 2023-05-09 | 2023-02-28 | 2022-11-08 | 2022-08-09 | 2022-05-10 | 2022-02-28 |
| Reported EPS | -0.37 | -0.36 | -0.58 | -0.62 | -1.63 | -0.8 | -0.74 | -0.95 | -1.17 | -0.88 | -0.94 | -0.93 |
| Estimated EPS | -0.38 | -0.53 | -0.75 | -0.72 | -0.85 | -0.78 | -0.7 | -0.95 | -0.89 | -0.86 | -0.83 | -1 |
| Surprise | 0.01 | 0.17 | 0.17 | 0.1 | -0.78 | -0.02 | -0.04 | 0 | -0.28 | -0.02 | -0.11 | 0.07 |
| Surprise Percentage | 2.6316% | 32.0755% | 22.6667% | 13.8889% | -91.7647% | -2.5641% | -5.7143% | 0% | -31.4607% | -2.3256% | -13.253% | 7% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RVNC
2026-02-27 06:52:00
Revance has launched its new StriVectin Barrier Restore+ Collection, which includes the Barrier Restore+ Soothing Ceramide Cream and Barrier Restore+ Soothing Milky Mist. This fragrance-free, sensitive skin line is designed to strengthen the skin barrier, soothe irritation, and address visible signs of aging. The products feature the new Turmeric-146 Peptide™ and StriVectin's proprietary NIA-114® technology, aiming to provide clinically proven results for sensitive skin.
2026-02-21 21:55:09
Revance has initiated a price reduction for its botulinum toxin treatment, Daxxify, in an effort to better compete with AbbVie's market-leading Botox, after struggling with its initial premium pricing strategy. Despite an initial drop in Revance's share price, analysts view this move positively, as the company aims to accelerate market expansion and increase Daxxify sales, noting encouraging early results in account orders. The company also expects to launch Daxxify for cervical dystonia following recent FDA approval, aiming to capitalize on a rapidly growing market.
2026-02-05 21:29:36
Revance Therapeutics, Inc. (RVNC) has been acquired by Crown Laboratories, Inc. through a cash tender offer and second-step merger. Following the acquisition, RVNC common stock will be delisted from NASDAQ, transitioning it into a historical ticker symbol. The article details Revance's business focus on aesthetic and therapeutic offerings, its product portfolio including DAXXIFY and RHA Collection, and its key partnerships and financial highlights leading up to the acquisition.
2026-01-12 13:58:46
Revance, a global leader in aesthetics and skincare, has appointed Steve Kreider as EVP, Chief Revenue Officer – Aesthetics and Therapeutics. In this new role, Kreider will oversee Revance's U.S. sales and revenue strategy across both its Aesthetics and Therapeutics businesses to drive sustainable growth and enhance provider engagement. This appointment aims to strengthen the company's commercial execution and expand its market impact.
2025-12-17 00:10:20
Kessler Topaz Meltzer & Check, LLP reminds investors of Revance Therapeutics, Inc. (NASDAQ:RVNC) about the February 8, 2022, lead plaintiff deadline in a securities fraud class action lawsuit. The lawsuit alleges that Revance made misleading statements regarding its business, operations, and prospects, leading to significant losses for investors. The alleged misconduct relates to FDA concerns about Revance's manufacturing facilities and the subsequent inability to approve its Biologics License Application for DAXI.
2025-12-09 09:03:00
Revance has launched the new StriVectin® TL Advanced Sculpting Neck & Jawline Mask, expanding its award-winning skincare portfolio. Formulated with proprietary Alpha-3 Peptide®, the mask is clinically proven to tighten, tone, and depuff the neck and jawline area, with visible results improving over time. It is currently available at Ulta and Strivectin.com, with wider availability in January 2026.
